Last reviewed · How we verify
L-Histidine
L-Histidine is an essential amino acid that serves as a precursor for histamine and other bioactive compounds involved in immune regulation, gastric acid secretion, and vasodilation.
L-Histidine is an essential amino acid that serves as a precursor for histamine and other bioactive compounds involved in immune regulation, gastric acid secretion, and vasodilation. Used for Histidine deficiency or supplementation in medical nutrition, Potential adjunctive use in immune support or inflammatory conditions.
At a glance
| Generic name | L-Histidine |
|---|---|
| Also known as | Histamine |
| Sponsor | University of Miami |
| Drug class | Amino acid supplement |
| Modality | Small molecule |
| Therapeutic area | Nutritional/Metabolic |
| Phase | FDA-approved |
Mechanism of action
L-Histidine is metabolized to histamine, which plays critical roles in immune responses, inflammation, gastric acid production, and vascular tone regulation. It also participates in protein synthesis and serves as a precursor for other important molecules including carnosine and anserine. As a nutritional supplement or pharmaceutical agent, L-Histidine may be used to support immune function, improve gastric health, or address histidine deficiency states.
Approved indications
- Histidine deficiency or supplementation in medical nutrition
- Potential adjunctive use in immune support or inflammatory conditions
Common side effects
- Gastrointestinal upset
- Allergic reactions (rare)
Key clinical trials
- Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (PHASE1)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Safety and Efficacy of Faricimab in Patients With NPDR (PHASE2)
- Essential Amino Acids and Parkinsons Disease (PHASE1)
- SMART Diets for MASLD (PHASE2)
- PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS) (NA)
- To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV (PHASE1)
- Study of Intravenous ZMA001 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Histidine CI brief — competitive landscape report
- L-Histidine updates RSS · CI watch RSS
- University of Miami portfolio CI